|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and more than 2,300 generic ingredients from more than 1,700 branded and generic pharmaceutical companies, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Generic Name: thalidomide
Summary for Generic Name: thalidomide
| |||||||||||||
Clinical Trials for: thalidomidePreoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall Status: Completed Condition: Recurrent Adult Soft Tissue Sarcoma; Stage I Adult Soft Tissue Sarcoma; Stage II Adult Soft Tissue Sarcoma; Stage III Adult Soft Tissue Sarcoma Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer Status: Recruiting Condition: Esophageal Cancer Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors Status: Completed Condition: Unspecified Adult Solid Tumor, Protocol Specific Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 Years Status: Active, not recruiting Condition: Multiple Myeloma Thalidomide Plus Dexamethasone as Maintenance Therapy for Multiple Myeloma Status: Completed Condition: Multiple Myeloma Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation Status: Completed Condition: Obscure Gastrointestinal Bleeding; Angiodysplasia; Gastric Antral Vascular Ectasia; Thalidomide TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy Status: Active, not recruiting Condition: Multiple Myeloma Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer Status: Completed Condition: Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer Status: Completed Condition: Prostate Cancer GEM05 for Patients With Multiple Myeloma Under 65 Years Status: Completed Condition: Multiple Myeloma Courtesy of ClinicalTrials.org See more clinical trials for this drug | |||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Patented / Exclusive Use | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Celgene | THALOMID | thalidomide | CAPSULE; ORAL | 020785 | Jul 16, 1998 | RX | No | <disabled> | ORPHAN DRUG EXCLUSIVITY | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE; ORAL | 020785 | Jul 16, 1998 | RX | No | 6,561,977 | <disabled> | APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE; ORAL | 020785 | Jul 16, 1998 | RX | No | 6,908,432 | <disabled> | APPROVAL FOR MARKETING ONLY UNDER A SPECIAL RESTRICTION PROGRAM APPROVED BY FDA CALLED "SYSTEM FOR THALIDOMIDE EDUCATION AND PRESCRIBING SAFETY" (S.T.E.P.S.) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Celgene | THALOMID | thalidomide | CAPSULE; ORAL | 020785 | Jul 16, 1998 | RX | No | 6,869,399 | <disabled> | MAINTENANCE THERAPY FOR PREVENTION AND SUPRESSION OF THE CUTANEOUS MANIFESTATIONS OF ENL RECURRENCE | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc